Jonathan Bui, MD
Internal Medicine · Waterloo, IANPI 1780115964
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 76 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 23 manufacturers, the largest accounting for just 11.4% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $567, 4.9 times the $116 reported in 2021. Among internal medicine clinicians in IA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 76 payments — averaging $21.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$188
- AbbVie$155
- Novo Nordisk$148
- Pfizer$141
- Johnson & Johnson$140
- E.r. Squibb & Sons, L.L.C.$118
- plus $753 from 17 others
What the payments were for
- Food & beverage$1,643100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 6 | $188 |
| AbbVie | 10 | $155 |
| Novo Nordisk | 7 | $148 |
| Pfizer | 7 | $141 |
| Johnson & Johnson | 4 | $140 |
| E.r. Squibb & Sons, L.L.C. | 7 | $118 |
| Phathom Pharmaceuticals, Inc. | 4 | $116 |
| Boehringer Ingelheim | 5 | $109 |
| Axsome Therapeutics, Inc. | 1 | $95 |
| Lilly USA, LLC | 4 | $61 |
| Novartis | 4 | $59 |
| Sanofi | 1 | $42 |
| Amgen | 3 | $42 |
| Vertex | 2 | $34 |
| Bayer | 2 | $29 |
| Idorsia Pharmaceuticals US Inc | 2 | $29 |
| Sanofi Pasteur Inc. | 1 | $27 |
| GSK | 1 | $23 |
| Merck | 1 | $19 |
| Exact Sciences | 1 | $19 |
| Xeris Pharmaceuticals, Inc. | 1 | $17 |
| Teva Pharmaceuticals USA, Inc. | 1 | $16 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $13 |
How this compares
$1,643 in reported general payments places this provider in the 90th percentile of 583 internal medicine providers in Iowa.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 160 | $162,636 |
| EliquisApixaban | 153 | $111,777 |
| XifaxanRifaximin | 45 | $97,743 |
| JardianceEmpagliflozin | 116 | $92,973 |
| MounjaroTirzepatide | 81 | $92,879 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 83 | $56,825 |
| XareltoRivaroxaban | 38 | $50,710 |
| Nucynta ErTapentadol Hcl | 13 | $34,880 |
| FarxigaDapagliflozin Propanediol | 30 | $33,263 |
| TrulicityDulaglutide | 32 | $32,178 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 31 | $20,782 |
| EntrestoSacubitril/Valsartan | 26 | $19,734 |
| WegovySemaglutide | 14 | $18,227 |
| JanuviaSitagliptin Phosphate | 19 | $15,304 |
| MyrbetriqMirabegron | 26 | $14,732 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Wegovy | $148 | $180,862174 claims |
| Lilly USA, LLCMounjaro, Trulicity | $61 | $125,057113 claims |
| PfizerEliquis | $141 | $111,777153 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan | $13 | $97,74345 claims |
| Boehringer IngelheimJardiance | $109 | $92,973116 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Shingrix | $23 | $76,893134 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort | $188 | $57,07574 claims |
| Johnson & JohnsonXarelto | $140 | $50,71038 claims |
| MerckJanuvia, Belsomra | $19 | $22,04835 claims |
| NovartisEntresto | $59 | $19,73426 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 583 internal medicine providers in Iowa.
Other internal medicine in Waterloo
- Mark JohnsonMason City$223K
- Mark CarlsonSioux City$174K
- Madalyn WalshIowa City$80K
- Alan KricsfeldCouncil Bluffs$49K
- Aziz HammoudIowa City$29K
- Matthew FryzekCouncil Bluffs$28K
- Diana Rabadi MararCouncil Bluffs$25K
- Isam MararCouncil Bluffs$23K
- Ali SaeedCedar Rapids$17K
- Lazaro RabangUrbandale$17K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.